One Million Dollars awarded to Institute for Myeloma and Bone Cancer Research
FJC, a foundation of philanthropic donor-advised funds, is the latest organization to grant major funding to the “Cure Myeloma Project”, an ongoing research initiative at the Institute for Myeloma and Bone Cancer Research, (IMBCR), in Los Angeles, CA Los Angeles CA – IMBCR’s “Cure Myeloma Project” is the nation’s foremost effort to find a cure for multiple myeloma, a common form of bone marrow cancer. Led by premier scientists in the world of myeloma research, James R. Berenson, M.D., Haiming Chen, M.D., Ph.D. and Zhi-Wei Li, Ph.D., this grant will cover six research projects: Tumor Necrosis Factor Receptor 6 Dominant Negative Peptides; Targeting and Activation of Cytotoxic Treatments within Tumor Cells Using Myeloma-Specific Oligonucleotides; Developing Anti-PTN Receptor Neutralizing Antibodies; Myeloma Stem Cells; Treatment of Metastatic Cancers, including Breast, Prostate, and Pancreatic Cancers with Pleiotrophin; Development of Additional SCID-hu Models of other Cancers.
A study published by the American Society of Hematology reports that while multiple myeloma remains incurable, the overall survival has improved because of new treatment options that have been recently made available. The average survival remains less than five years from diagnosis. The American Cancer Society predicts that over 80,000 people are currently living with myeloma in the US and over 20,000 new cases are diagnosed each year. Approximately 10,000 people die each year from multiple myeloma. About FJC: Established in 1995 by a small group of dedicated philanthropists, FJC was created with the goal of making it the premier group of donor advised funds.
Today, FJC is a public charity that provides total management of charitable giving and operates a nationally recognized donor advised fund, a non profit Agency Loan Fund and provides fiscal sponsorship for creative and innovative charitable projects. To date, over $100,000,000 in grants has been made to charities in the United States and around the world.
About IMBCR: The Institute for Myeloma and Bone Cancer Research, established in 2004 as a 501 (c) (3) non-profit organization, is headquartered in Los Angeles, CA. IMBCR is the only independent non-profit cancer research institute working to find improved treatment, and ultimately a cure for multiple myeloma. IMBCR research is funded in part by donations from the Annenberg, Skirball, Lincy and Kramer Family Foundations, Multiple Myeloma Research Foundation and Myeloma Research Fund. Collaborative research is also sponsored by major pharmaceutical companies. www.imbcr.org